Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 3, 2004, Pages 839-846

  Yildiz, Ferah ^a   Zengin, Nurullah ^b   Engin, Hüseyin ^a   Güllü, Ibrahim ^a   Barista, Ibrahim ^a   Çaglar, Meltem ^a   Özyar, Enis ^a   Cengiz, Mustafa ^a   Gürkaynak, Murat ^a   Zorlu, Faruk ^a   Caner, Biray ^a   Atahan, I Lale ^a   Tekuzman, Gülten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Early stage; Hodgkin's disease; Treatment

Indexed keywords

CHEMOTHERAPY; DISEASE CONTROL; MEDICAL IMAGING; MODAL ANALYSIS; PATIENT MONITORING; TOXICITY;

COMBINED MODALITY TREATMENT (CMT); NODAL AREAS; SEDIMENTATION RATE;

RADIOTHERAPY;

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION FIELD; RADIOSENSITIVITY; RELAPSE; SCLEROSIS; STATISTICAL SIGNIFICANCE; TOXICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; SALVAGE THERAPY; SURVIVAL RATE; VINBLASTINE;

EID: 4744348272     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.04.002     Document Type: Article

References (23)

1. Specht L. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol. 6:1996;146-161
2. Aisenberg A.C. Problems in Hodgkin's disease management. Blood. 93:1999;761-779
3. Leibenhaut M.H., Hoppe R.T., Efron S., et al. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol. 7:1989;81-89
4. Mauch P., Larson D., Osteen R., et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol. 8:1990;257-265
5. Specht L., Grey R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long term outcome of early-stage Hodgkin's disease A metaanalysis of 23 randomized trials involving 3888 patients. J Clin Oncol. 16:1998;830-843
6. Carde P., Burger J.M., Henry-Amar M. Clinical stage I and II Hodgkin's disease A specifically tailored therapy according to prognostic factors. J Clin Oncol. 6:1988;239-245
7. Loeffler M., Pfreundschuh M., Rühl U. Risk factor adapted treatment of Hodgkin's lymphoma Strategies and perspectives. Recent Results Cancer Res. 117:1989;142-153
8. Tubiana M., Henry-Amar M., Carde P. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease The EORTC Lymphoma Group controlled clinical trials - 1964-1987. Blood. 73:1989;47-59
9. Noordijk E., Carde P., Hagenbeek A., et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease. Ann Oncol. 5:1994;107-112
10. Hagenbeek A., Carde P., Noordijk E., et al. Prognostic factor tailored treatment of early stage Hodgkin's disease Results of a prospective randomized stage III clinical trial in 762 patients (H7 study). [Abstract] Blood. 90:(Suppl. 1):1997;565a
11. Duhmke E., Diehl V., Loeffler M., et al. Randomized trial with early stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 36:1996;305-312
12. Bonfante V, Viviani S, Devizz IL, et al. Ten years experience with ABVD plus radiotherapy: Subtotal nodal (STNI) vs. involved field radiotherapy (IFRT) in early stage Hodgkin's disease [Abstract]. Proc Am Soc Clin Oncol 2001;281a
13. Ferme C., Eghbali H., Hagenbeek A., et al. MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II HD Comparison of three treatment modalities, preliminary results of EORTC-GELA H8U randomized trial in 995 patients. [Abstract] Blood. 96:2000;576a
14. Engert A., Schiller P., Josting A., et al. Involved field (IF) radiotherapy is effective and less toxic compared with extended field radiotherapy after 4 cycles of chemotherapy in patients with early stage unfavorable Hodgkin's lymphoma Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 21:2003;3601-3608
15. Connors JM, Noordijk EM, Horning S. Hodgkin's lymphoma: Basing the treatment on evidence. Hematology (Am Soc Hematol Educ Program) 2001;1:178-193
16. Maity A., Goldwein J.W., Lange B., et al. Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania. J Clin Oncol. 10:1992;929-935
17. Hudson M.M., Greenwald C., Thompson E., et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 11:1993;100-108
18. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: Biology and treatment strategies for primary, refractory and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003;1:225-247
19. Meyer R, Gospodarowicz M, Connors J, et al. A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06). Blood 2003;102:81a
20. le Maignan C., Desablens B., Delwail V., et al. Three cycles of adriamycin, bleomycin, vinblastine and methotrexate (ABVD) or epirubicin, bleomycin, vinblastine and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease 10-year results of a randomized trial. Blood. 103:2004;58-66
21. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1:1995;33-42
22. Chronowski G., Wilder R.B., Tucker S.L., et al. Analysis of in-field control and late toxicity for adults with early stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 55:2003;36-43
23. Gobbi P., Broglia C., Merli F., et al. Vinblastine, bleomycin and methotrexate chemotherapy plus irradiation for patients with early stage favorable Hodgkin's lymphoma The experience of the Gruppo Italiano Studio Linfomi. Cancer. 98:2003;2393-2401